68
Participants
Start Date
August 29, 2016
Primary Completion Date
October 10, 2018
Study Completion Date
April 3, 2019
Olaratumab
Olaratumab administered IV.
Doxorubicin
Doxorubicin administered IV.
Vincristine
Vincristine administered IV.
Irinotecan
Irinotecan administered IV.
Ifosfamide
Ifosfamide administered IV.
Memorial Sloan Kettering Cancer Center, New York
Cohen Children's Medical Center, New Hyde Park
Levine Children's Hospital, Charlotte
Sylvester Comprehensive Cancer Center, Miami
St Jude Childrens Research Hospital, Memphis
Riley Hosptial for Children, Indianapolis
University of Minnesota Medical School, Minneapolis
Children's Mercy Hospital, Kansas City
Mary Crowley Cancer Research Center, Dallas
University of Texas Southwestern Medical Center at Dallas, Dallas
Texas Childrens Hospital, Houston
The Children's Hospital for Cancer and Blood Disorders, Aurora
Primary Childrens Medical Center, Salt Lake City
Phoenix Childrens Hospital, Phoenix
Childrens Hospital of Los Angeles, Los Angeles
University of California, San Francisco, San Francisco
Seattle Children's Hospital Research Foundation, Seattle
Children's National Medical Center, Washington D.C.
Dana Farber Cancer Institute, Boston
Vanderbilt University Medical Center, Nashville
National Cancer Center Hospital, Chuo-Ku
Eli Lilly and Company
INDUSTRY